# NeuroAI Implementation Roadmap

**Status**: Comprehensive development plan for full-stack neurodegenerative drug discovery platform with Android deployment.

## Project Overview

This document details the iterative development of a multimodal AI platform for neurodegenerative drug discovery, integrating:
- Machine Learning/Deep Learning models for molecular representation and disease modeling
- MedGemma-powered medical reasoning and validation
- Constraint-based reinforcement learning for drug sequencing
- Android mobile application for clinical decision support
- Production-grade backend infrastructure

## Phase 1: Foundation & Core ML Components (Weeks 1-2)

### 1.1 Database Schema & Knowledge Graph
- **Objective**: Establish comprehensive data models for biological entities
- **Components**:
  - ✅ Enhanced Django models for diseases, pathways, drugs, targets
  - [ ] Neo4j integration for knowledge graphs
  - [ ] Migration system for disease networks
  - [ ] Provenance and audit trail system

**Key Models**:
```
Disease -> [has_pathways] -> Pathway -> [targets_protein] -> Target
Drug -> [modulates_target] -> Target -> [affects_pathway] -> Pathway
         |-> [has_adverse_target] -> Target
Patient -> [has_disease_state] -> DiseaseState -> [progression] -> Timeline
```

### 1.2 Molecular Representation Framework
- **Objective**: Implement multi-view molecular representations
- **Models to Implement**:
  - Graph Neural Networks (GNN) for molecular structures
  - Transformer-based sequence models (ESM for proteins)
  - Molecular fingerprinting (ECFP, Morgan)
  - Physicochemical descriptor extraction

**Papers & References**:
- SchNet: A continuous-filter convolutional neural network for modeling quantum interactions (2018)
- Message Passing Neural Networks for Partial Differential Equations (2021)
- Protein language models capture structure and function of viral proteins (ESM, 2023)

**Implementation Stack**:
- PyTorch + PyG (PyTorch Geometric) for GNNs
- HuggingFace for protein language models
- RDKit for cheminformatics

### 1.3 Target Engagement Prediction
- **Objective**: Predict drug-target binding affinities and off-target effects
- **Approach**:
  - Graph Neural Network for ligand representation
  - Attention mechanisms for target pocket encoding
  - Multi-task learning for cross-target generalization
  
**Papers**:
- AttentionSite: Multi-task Attention for Drug-Target Interaction Prediction (submitted)
- GraphDTA: Prediction of compound-protein interactions (2020)
- DeepDTA: Deep learning for Drug-Target Binding Affinity prediction (2018)

### 1.4 Pathway Perturbation Models
- **Objective**: Model how drugs affect biological pathways
- **Components**:
  - Knowledge graph embeddings (TransE, DistMult)
  - Dynamical systems models for pathway kinetics
  - Uncertainty quantification (Bayesian deep learning)

**Papers**:
- Knowledge Graphs as Foundation for Large Language Models (2024)
- Uncertainty in Graph Neural Networks for Drug Discovery (2022)

## Phase 2: Disease Modeling & Phenotypic Simulation (Weeks 3-4)

### 2.1 Disease State Representation
- **Objective**: Encode patient-specific disease trajectories
- **Approach**:
  - Variational Autoencoders (VAE) for disease state encoding
  - Latent space represents disease severity, pathway dysregulation
  - Time-series models capture disease progression

**Papers**:
- Learning Latent Representations for Phenotypic Outcomes (2020)
- Variational Recurrent Auto-Encoders for Disease Progression (2019)

### 2.2 Disease Trajectory Prediction
- **Objective**: Predict how disease will progress given interventions
- **Models**:
  - Neural ODE for continuous-time disease dynamics
  - Temporal point processes for event prediction
  - Gaussian processes for uncertainty quantification

**Papers**:
- Neural Ordinary Differential Equations (2018) - TorchDyn
- Latent ODE: Ordinary Differential Equations for Sequence Modeling (2020)
- Learning Disease Trajectories with Causal Neural ODEs (2023)

## Phase 3: MedGemma Integration & Reasoning (Weeks 5-6)

### 3.1 Medical Knowledge Reasoning
- **Objective**: Use MedGemma for biological plausibility checking
- **Tasks**:
  - Validate if drug-target predictions are mechanistically sound
  - Generate mechanistic explanations for predictions
  - Detect contradictions across multiple evidence sources
  - Summarize uncertainty in accessible language

**Prompt Engineering Strategies**:
- Few-shot prompting with domain examples
- Chain-of-thought prompting for complex reasoning
- Constraint-based generation to prevent hallucination
- Citation-grounded responses using RAG

### 3.2 Retrieval-Augmented Generation (RAG)
- **Objective**: Ground MedGemma responses in curated evidence
- **Components**:
  - Vector database for biomedical literature (ChromaDB)
  - Semantic search over drug, target, pathway information
  - Result re-ranking and citation extraction

**Papers**:
- Retrieval-Augmented Generation for Knowledge-Intensive NLP Tasks (2020)
- In-Context Retrieval-Augmented Language Models (2023)

### 3.3 Explainability Generation
- **Objective**: Produce human-readable mechanistic explanations
- **Approach**:
  - Attention visualization from neural models
  - SHAP values for model contribution analysis
  - Natural language generation of key findings

**Papers**:
- Explaining Neural Networks through Pertinent Image Regions (2016)
- A Unified Framework for Interpreting Model Predictions (SHAP, 2017)

## Phase 4: Constraint-Based Reinforcement Learning (Weeks 7-8)

### 4.1 Safe Policy Learning
- **Objective**: Learn drug sequencing policies that respect safety constraints
- **Approach**:
  - Constrained Markov Decision Process (C-MDP)
  - Lagrangian relaxation for constraint satisfaction
  - Curriculum learning starting from simple policies

**Papers**:
- Constrained Policy Optimization (2017)
- Reward Constrained Policy Optimization (2019)
- Safe Reinforcement Learning in Constrained MDPs (2020)

### 4.2 Offline RL & Batch Learning
- **Objective**: Learn from existing clinical data without online interaction
- **Methods**:
  - Conservative Q-Learning (CQL)
  - Batch Constrained Deep Q-Learning (BCQ)
  - Model-based offline RL with uncertainty

**Papers**:
- Conservative Q-Learning for Offline Reinforcement Learning (2020)
- Batch Constrained Deep Q-Learning (2019)

## Phase 5: Validation Framework (Weeks 9-10)

### 5.1 Computational Validation
- **Objective**: Validate models against known drug-disease associations
- **Methods**:
  - Cross-validation on benchmark datasets
  - Ablation studies
  - Fairness auditing across patient subgroups

**Benchmarks**:
- KIBA dataset for drug-target binding
- BioSNAP for knowledge graph completion
- Clinical trial data (simulate)

### 5.2 Experimental Validation Design
- **Objective**: Design experiments to test top predictions
- **Output**: Suggested experimental protocols
- **Framework**: Integration with DrugBank, PubChem data

## Phase 6: Android Mobile App Development (Weeks 11-12)

### 6.1 Architecture
- **Backend API**: Django REST APIs (already scaffolded)
- **Frontend**: Kotlin/Jetpack Compose for native Android
- **Local Inference**: TensorFlow Lite for on-device models
- **Sync**: Background sync with cloud backend

### 6.2 Key Screens
1. **Patient Overview**: Disease state, key metrics, timeline
2. **Drug Recommendations**: Top candidates with mechanism visualization
3. **Pathway Analysis**: Interactive pathway visualization
4. **Risk Assessment**: Safety scores, adverse target analysis
5. **Explanation Engine**: Detailed mechanism breakdowns

### 6.3 Technical Stack
```
Android Frontend:
- Kotlin + Jetpack Compose (UI)
- Retrofit + OkHttp (Network)
- Room (Local database)
- Hilt (Dependency injection)
- TensorFlow Lite (Local inference)
- Jetpack WorkManager (Background tasks)

Integration:
- GraphQL or REST API client
- Real-time updates (WebSocket)
- Offline-first architecture
- Data encryption at rest
```

**Papers**:
- TensorFlow Lite: Efficient On-Device ML (2019)
- Mobile and Embedded Vision: TensorFlow on Device (2020)

## Phase 7: Docker & Deployment Infrastructure (Weeks 13-14)

### 7.1 Containerization
- **Components**:
  - Django/DRF API service
  - MedGemma inference service (vLLM)
  - ML model serving (BentoML or KServe)
  - PostgreSQL with vector extensions (pgvector for embeddings)
  - Redis for caching
  - Celery workers for async tasks

### 7.2 Orchestration
- **Kubernetes manifests** for cloud deployment
- **Helm charts** for templating
- **CI/CD pipeline** with GitHub Actions
- **Monitoring** (Prometheus, Grafana)
- **Logging** (ELK stack integration)

## Phase 8: Documentation & Technical Report (Weeks 15-16)

### 8.1 Technical Documentation
- API endpoint specifications (OpenAPI/Swagger)
- ML model architecture diagrams
- Database schema documentation
- Deployment guides
- Troubleshooting documentation

### 8.2 Scientific Report
- Executive summary
- Literature review with citations
- System architecture with justifications
- Experimental validation results
- Ethical and regulatory considerations
- Future work and extensions

### 8.3 User Guides
- Clinical user manual
- Researcher API documentation
- Mobile app user guide
- System administrator manual

## Key Technologies & Libraries

### ML/DL Stack
```
PyTorch (1.13+)
PyTorch Geometric (2.3+)
Transformers (HuggingFace 4.30+)
ESM (Protein language models)
Ray (distributed computing)
scikit-learn
scipy
networkx
```

### Bioinformatics & Chemistry
```
RDKit (molecular representations)
BioPython (sequence analysis)
drugbank (knowledge base)
pubchem (chemical data)
UniProt (protein data)
```

### Web Backend
```
Django 5.0+
Django REST Framework
Celery + Redis
PostgreSQL 15+
pgvector (vector embeddings)
Neo4j (optional, knowledge graphs)
```

### LLM & RAG
```
MedGemma (via Google API or vLLM)
vLLM (optimized inference)
ChromaDB (vector storage)
Langchain (LLM orchestration)
OpenAI API (fallback reasoning)
```

### Frontend
```
React 18 (Web)
Kotlin + Jetpack Compose (Android)
TypeScript
TailwindCSS
D3.js / Plotly (Visualizations)
```

### DevOps
```
Docker & Docker Compose
Kubernetes
GitHub Actions
Prometheus & Grafana
ELK Stack
SonarQube
```

## Success Metrics

### Phase Completion Metrics
1. **ML Models**: 
   - Drug-target binding AUC > 0.85
   - Pathway perturbation RMSE < 0.2
   - Disease trajectory MAE < 5%

2. **Validation**:
   - > 80% of top-5 predictions validated in literature
   - > 3 novel drug-disease associations identified

3. **System Performance**:
   - API response time < 500ms
   - MedGemma explanation generation < 10s
   - Mobile app cold start < 5s

4. **User Adoption**:
   - 50+ research users in pilot
   - > 80% satisfaction on explainability
   - > 90% uptime SLA

## Risk Mitigation

| Risk | Probability | Impact | Mitigation |
|------|------------|--------|-----------|
| Data quality issues | High | High | Implement validation layers, manual review |
| Model overfitting | High | Medium | Cross-validation, regularization, external validation |
| MedGemma hallucination | Medium | High | RAG, constraint-based generation, human review |
| Android deployment complexity | Medium | Medium | Use established frameworks, extensive testing |
| Regulatory compliance | Medium | High | Work with domain experts, document everything |

## Timeline

```
Week 1-2:   Phase 1 - Foundation
Week 3-4:   Phase 2 - Disease Modeling
Week 5-6:   Phase 3 - MedGemma Integration
Week 7-8:   Phase 4 - RL Policy Learning
Week 9-10:  Phase 5 - Validation
Week 11-12: Phase 6 - Android Development
Week 13-14: Phase 7 - Deployment
Week 15-16: Phase 8 - Documentation & Report
```

## Current Status

✅ Django backend scaffolding
✅ React frontend basic structure
✅ Basic drug/target/pathway models
⏳ ML components (in progress)
⏳ MedGemma integration
⏳ Android app development
⏳ Documentation & report

## Next Steps

1. Enhance requirements.txt with all ML/DL dependencies
2. Implement molecular representation models
3. Create disease state and trajectory models
4. Integrate MedGemma with caching and rate limiting
5. Begin Android app development
